Resident
Gacic, Nikolina, PharmD
Residency Program
LMPS
Project Title
Daily Ritonavir-boosted darunavir for Viral suppression
Investigators
Tulloch, Karen (BSc Pharm, PharmD, ACPR), Tkachuk, Stacey (BSc Pharm, PharmD, ACPR), Money, Deborah (MD, FRCSC)
Abstract
Ritonavir-boosted darunavir (DRV/r) is a preferred protease inhibitor in pregnant persons living with HIV (PLWH). Current practice at Oak Tree Clinic is to dose DRV/r as 800/100 mg daily throughout pregnancy, although guidelines recommend DRV/r 600/100 mg twice daily due to decreased plasma trough levels with once daily dosing. The purpose of this study was to describe the effect of once daily DRV/r on viral suppression, perinatal HIV transmission, adverse drug effects and adherence in pregnant PLWH. DRV/r 800/100 mg daily was found to be an appropriate dosing strategy for pregnant persons who were able to maintain optimal adherence.
